The United States represents the largest share of the diabetes therapeutics market, driven by the high prevalence of diabetes, advanced healthcare infrastructure, and strong adoption of innovative treatment solutions. According to health authorities, millions of Americans are living with diabetes, creating substantial demand for insulin products, GLP-1 receptor agonists, SGLT2 inhibitors, and...